Last reviewed · How we verify
NCT03153371: EOAD-Subtype
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
trial in Alzheimer Disease, Early Onset in 180 participants. Completed in 31 August 2021.
31 August 2021
Quick facts
| Lead sponsor | University of California, Los Angeles |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 4 April 2016 |
| Primary completion | 31 August 2021 |
| Estimated completion | 31 August 2021 |
| Sites | 1 location across United States |
Conditions studied
- Alzheimer Disease, Early Onset — all drugs for Alzheimer Disease, Early Onset →
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Alzheimer Disease, Late Onset — all drugs for Alzheimer Disease, Late Onset →
- Dementia, Alzheimer Type — all drugs for Dementia, Alzheimer Type →
Sponsor
University of California, Los Angeles
Who can join
Adults 50 to 85, any sex, with Alzheimer Disease, Early Onset or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03153371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease, Early Onset
Currently open trials in the same condition.
- NCT06814730 — A Study to Assess THN391 in Subjects With Alzheimer's Disease · Phase 1 · recruiting
- NCT06688968 — Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease · NA · recruiting
- NCT06668610 — A Multifocal TDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia · NA · recruiting
- NCT06268886 — Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Partici · Phase 2 · active not recruiting
- NCT05983575 — A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease · Phase 3 · active not recruiting
Other University of California, Los Angeles trials
Trials by the same sponsor.
- NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
- NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
- NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03153371 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03153371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing